Tenderwize
Retour à la recherche

Accord de rabais pour médicaments à base d’urapidil

AOK Niedersachsen. Die Gesundheitskasse.·Hannover, Germany·Deadline Nov 27, 2027 · 371 days left·Open·Supplies·Framework
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Urapidil (ATC-Code: C02CA06).

48/100

Score d'opportunité

Needs reviewHigh complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

48 / 100

Complexité

69 / 100

Facteurs de risque

The notice provides no estimated value, guaranteed volume or demand commitment, and the agreement is expressly non-excl...

AOK may replace the open-house agreements with exclusive agreements, causing the open-house contracts to end automatica...

No procurement documents available

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
AOK Niedersachsen. Die Gesundheitskasse.
Pays
Allemagne
CPV
33600000 - Pharmaceutical products
Date limite
Nov 27, 2027

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Provision of medicinal products containing the active substance Urapidil, ATC code C02CA06, under a non-exclusive discount agreement with AOK Niedersachsen.
  • Open-house participation is available to all interested eligible pharmaceutical companies without an individual selection decision.
Afficher le résumé complet

AOK Niedersachsen is offering a non-exclusive open-house pharmaceutical discount agreement for medicinal products containing Urapidil (ATC C02CA06) in Germany. Eligible pharmaceutical entrepreneurs may join on uniform, non-negotiable conditions without a selection decision. The arrangement is intended to run from 1 February 2026 until 31 January 2028, but may end earlier if exclusive agreements enter into force. No contract value or guaranteed purchase volume is stated. The initial joining deadline is 29 December 2025, while the structured notice gives a later overall deadline of 27 November 2027; this should be clarified. The tender documents were not provided or analyzed.

Risques

The notice provides no estimated value, guaranteed volume or demand commitment, and the agreement is expressly non-excl...

AOK may replace the open-house agreements with exclusive agreements, causing the open-house contracts to end automatica...

No procurement documents available

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • The contracting party must be a pharmaceutical entrepreneur within the meaning of Section 4(18) AMG, or a consortium of pharmaceutical entrepreneurs, in relation to the...
  • The pharmaceutical entrepreneur must have its registered seat in Germany, another EU Member State, or another EEA contracting state, as stated in the notice.
  • A local representative may participate only if it independently qualifies as a pharmaceutical entrepreneur for the medicinal products concerned.

Critères d'attribution

Lot 1

Price is identified as the award criterion, but no description or weighting is provided. In the open-house model, participation is described as being without a selection decision.

Acheteur

Localisation

Hannover, DEU

Identifiant

AOK- Niedersachsen. Die Gesundheitskasse

Activité

Health

Lots (1)

LOT-0000

Urapidil non-exclusive discount agreement

Non-exclusive open-house discount agreement under Section 130a(8) SGB V for medicinal products containing Urapidil (ATC C02CA06). All interested eligible pharmaceutical companies may join under identical conditions. Contracts may be concluded during the period, with automatic or earlier termination possible if exclusive agreements enter into force.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE929, Germany

Durée

Jan 2026 - Jan 2028

Catégorie

Pharmaceutical products

Critères d'attribution

Price

Date limite

Deadline Nov 27, 2027

Détails de la procédure

Date de publication
08 Dec 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
815102-2025

Appels d'offres similaires

Cookies & Privacy

With your consent, we use Google Analytics, Microsoft Clarity (session recordings) and Google Ads cookies to understand how Tenderwize is used and to measure our advertising. You can change your choice at any time via “Cookie Settings” in the footer. Cookie Policy · Privacy Policy